to the risk of heart attack or stroke," he said in an interview.
"I think it's good we are looking at safety," Wilson said.
The drug was not pulled at that point.
"He did so voluntarily," the agency said.
This is a safety issue, but also an economic one.
In addition to Bextra, Pfizer also makes Celebrex, the best-selling COX-2 drug on the market.
With Vioxx, researchers had been warning about the drug's possible cardiovascular risks since 2000, only a year after it was approved by the FDA.
``That's the tragedy here.''
``I thought the risk was going to be larger than it was,'' he said.
